40.78 USD
-1.27 (-3.02%)
40.78 USD
0 (0%)
Taking everything into account, RIGL scores 7 out of 10 in our fundamental rating. RIGL was compared to 531 industry peers in the Biotechnology industry. RIGL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RIGL is evaluated to be cheap and growing strongly. This does not happen too often! This makes RIGL very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
In the past year RIGL was profitable.
In the past year RIGL had a positive cash flow from operations.
RIGL had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of RIGL (46.72%) is better than 99.25% of its industry peers.
RIGL has a Return On Equity of 96.34%. This is amongst the best in the industry. RIGL outperforms 99.44% of its industry peers.
RIGL has a better Return On Invested Capital (63.44%) than 99.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RIGL's Profit Margin of 40.17% is amongst the best of the industry. RIGL outperforms 96.80% of its industry peers.
With an excellent Operating Margin value of 42.17%, RIGL belongs to the best of the industry, outperforming 98.68% of the companies in the same industry.
Looking at the Gross Margin, with a value of 93.10%, RIGL belongs to the top of the industry, outperforming 93.60% of the companies in the same industry.
RIGL's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
RIGL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RIGL has less shares outstanding
Compared to 1 year ago, RIGL has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.41, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.41, RIGL perfoms like the industry average, outperforming 56.87% of the companies in the same industry.
The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.88, RIGL belongs to the top of the industry, outperforming 93.79% of the companies in the same industry.
RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.25, RIGL is not doing good in the industry: 68.17% of the companies in the same industry are doing better.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -0.41 |
ROIC/WACC7.16
WACC8.86%
2.3 Liquidity
RIGL has a Current Ratio of 2.28. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
RIGL has a worse Current ratio (2.28) than 74.01% of its industry peers.
A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
RIGL has a Quick ratio of 2.14. This is in the lower half of the industry: RIGL underperforms 73.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4307.14%, which is quite impressive.
Looking at the last year, RIGL shows a very strong growth in Revenue. The Revenue has grown by 79.13%.
The Revenue has been growing by 24.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
Based on estimates for the next years, RIGL will show a very strong growth in Earnings Per Share. The EPS will grow by 36.89% on average per year.
The Revenue is expected to grow by 15.70% on average over the next years. This is quite good.
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y36.89%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 6.61, which indicates a rather cheap valuation of RIGL.
Compared to the rest of the industry, the Price/Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.68% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.54, RIGL is valued rather cheaply.
RIGL is valuated reasonably with a Price/Forward Earnings ratio of 9.27.
RIGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.68% of the companies in the same industry.
RIGL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.78.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | 9.27 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaper than 98.87% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, RIGL is valued cheaper than 97.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.86 | ||
| EV/EBITDA | 4.92 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RIGL may justify a higher PE ratio.
RIGL's earnings are expected to grow with 80.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y116.3%
EPS Next 3Y80.91%
5. Dividend
5.1 Amount
RIGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
40.78
-1.27 (-3.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.02%
Inst Owner Change8.17%
Ins Owners2.55%
Ins Owner Change0%
Market Cap740.16M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target46.24 (13.39%)
Short Float %17.6%
Short Ratio4.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)18.26%
PT rev (3m)18.26%
EPS NQ rev (1m)13.05%
EPS NQ rev (3m)42.6%
EPS NY rev (1m)17.94%
EPS NY rev (3m)17.94%
Revenue NQ rev (1m)0.85%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)3.5%
Revenue NY rev (3m)3.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | 9.27 | ||
| P/S | 2.62 | ||
| P/FCF | 10.86 | ||
| P/OCF | 10.86 | ||
| P/B | 6.29 | ||
| P/tB | 8.02 | ||
| EV/EBITDA | 4.92 |
EPS(TTM)6.17
EY15.13%
EPS(NY)4.4
Fwd EY10.78%
FCF(TTM)3.75
FCFY9.21%
OCF(TTM)3.76
OCFY9.21%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -0.41 |
F-Score7
WACC8.86%
ROIC/WACC7.16
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y36.89%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year525.53%
EBIT Next 3Y109.33%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
Can you provide the valuation status for RIGEL PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for RIGL stock?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 611.29% in the next year.